Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models
Our results demonstrate the utility of transient mRNA CAR T cells delivered intratumorally to provide effective tumor killing with a defined half-life, allowing for modulation of the dose and potential side effects. We anticipate this study will expand the use of CAR T cell therapy for DMG and other central nervous system tumors and non-malignant disorders, where concern for toxicity from permanently expressing CAR T cells may hinder development.
Authors
- Conor Dickson
- Javad Nazarian (ORCID: https://orcid.org/0000-0002-1951-9828)
- Crystal Griffin
- Peter J. Madsen (ORCID: https://orcid.org/0000-0001-9266-3685)
- Nikhil Joshi (ORCID: https://orcid.org/0000-0001-9258-4960)
- Jessica Foster (ORCID: https://orcid.org/0000-0002-8001-5960)
- Nicholas A. Vitanza (ORCID: https://orcid.org/0000-0002-3966-4985)
- Luke Patterson
- Allison Stern
- Phillip B. Storm (ORCID: https://orcid.org/0000-0002-7964-2449)
- Kyra Harvey
- Valérie Baubet
- Mateusz Koptyra (ORCID: https://orcid.org/0000-0002-3857-6633)
- David Beale
- Adam Resnick (ORCID: https://orcid.org/0000-0003-0436-4189)
- Ezra Beaubien
- Cullen Wilson
- Olivia McManus
- Payush N Goel P
Institutions
- Seattle Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- University of Washington (US)
- University of Zurich (CH)
- Seattle Children's Hospital (US)
- Center for Cancer and Blood Disorders (US)
- University Children's Hospital Zurich (CH)
- University of Pennsylvania (US)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1093/neuonc/noaf115
- Citations
- 8
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 8.36